Back to products

Retatrutide 10mg/20mg Research Peptide

Name: Retatrutide 10mg/20mg Research Peptide
SKU: 15842
Price: 130.00 USD
Availability: InStock

Third-Party Tested

≥98% Purity

Fast Shipping

COA Included

For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.

$130.00

Compare

Add to wishlist

Shipping and returns

Authorities in our business will tell in no uncertain terms that Lorem Ipsum is that huge, huge no no to forswear forever. Not so fast, I'd say, there are some redeeming factors in favor of greeking text, as its use is merely the symptom of a worse problem to take into consideration.

Product care

Anyway, you still use Lorem Ipsum and rightly so, as it will always have a place in the web workers toolbox, as things happen, not always the way you like it, not always in the preferred order.

Product details

Made possible by exploring innovative molded plywood techniques, Iskos-Berlin’s Soft Edge Chair blends strong curves with extreme lightness to create a three-dimensionality not usually possible with 2-D plywood.

Description

For Research Purposes Only. Not approved for human consumption.

Retatrutide Research Peptide

Retatrutide is a synthetic triple hormone receptor agonist peptide developed by Eli Lilly — the first-in-class compound to simultaneously activate GLP-1, GIP, and glucagon receptors. In Phase 3 SURMOUNT trials, Retatrutide achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving ≥15% body weight reduction. It represents the most advanced metabolic peptide in clinical research, offering researchers a unique tool for studying triple-pathway metabolic regulation.

Research Applications

Triple hormone receptor (GLP-1/GIP/Glucagon) research
Metabolic rate and energy expenditure studies
Advanced obesity and weight regulation biology
Insulin sensitivity and glucose metabolism research
Combination incretin pathway investigations

Quality Specifications

Purity: ≥98% (HPLC verified)
Compound: Retatrutide
Molecular Weight: ~4.9 kDa
Form: Lyophilized powder
Storage: -20°C, protect from light
COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: What makes Retatrutide unique?
A: It is the first triple agonist (GLP-1 + GIP + Glucagon) studied in Phase 3 trials. Most metabolic peptides target one receptor; Tirzepatide targets two. Retatrutide targets all three simultaneously.

Q: What were the Phase 3 SURMOUNT-1 results?
A: 2,539 participants: 12mg dose achieved 24.2% mean weight loss; 8mg dose 22.8%; 91% achieved ≥15% reduction at highest dose. Published in NEJM 2023.

Q: How does the glucagon component work?
A: Low-level glucagon receptor activation may increase resting energy expenditure via thermogenesis and enhanced lipolysis — complementing the appetite-suppressing effects of GLP-1 and GIP.

For laboratory research use only. Not for human consumption. Not evaluated by the FDA.

Customer Reviews

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Peptides

$100.00